Intellia therapeutics, inc. (NTLA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Collaboration revenue

45,586

43,103

40,047

36,839

33,398

30,434

29,222

29,131

27,371

26,117

25,076

22,628

20,917

16,479

12,545

9,364

6,535

6,044

0

0

0

Operating expenses:
Research and development

119,354

108,413

96,600

92,324

90,331

89,115

90,367

84,611

76,709

67,647

57,808

48,188

40,046

31,840

24,884

20,481

15,024

11,170

0

0

0

General and administrative

41,839

41,058

40,790

40,629

35,316

32,189

33,694

31,135

29,699

28,025

22,930

21,924

19,284

16,798

14,489

11,315

10,419

8,283

0

0

0

Total operating expenses

161,193

149,471

137,390

132,953

125,647

121,304

124,061

115,746

106,408

95,672

80,738

70,112

59,330

48,638

39,373

31,796

25,443

19,453

0

0

0

Operating loss

-115,607

-106,368

-97,343

-96,114

-92,249

-90,870

-94,839

-86,615

-79,037

-69,555

-55,662

-47,484

-38,413

-32,159

-26,828

-22,432

-18,908

-13,409

0

0

0

Interest income

6,208

6,835

7,020

6,723

6,322

5,527

4,599

3,721

2,769

2,012

1,519

1,215

837

525

0

0

0

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,409

0

0

0

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,012

0

0

0

Net loss

-109,399

-99,533

-90,323

-89,391

-85,927

-85,343

-90,240

-82,894

-76,268

-67,543

-54,143

-46,269

-37,576

-31,634

-26,316

-21,853

-17,993

-12,397

0

0

0

Net loss per share, basic and diluted

-0.63

-0.57

-0.49

-0.56

-0.49

-0.43

-0.53

-0.52

-0.51

-0.61

-0.44

-0.45

-0.36

-0.31

-0.22

-0.36

-9.89

-9.57

-10.27

-2.37

-0.85

Weighted average shares outstanding, basic and diluted

50,491

49,350

48,554

45,814

45,234

44,215

43,161

42,836

42,043

39,155

35,189

34,916

34,723

34,507

34,316

19,121

676

548

294

1,284

1,284

Other comprehensive loss:
Unrealized gain on marketable securities

314

289

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-109,085

-99,244

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-